NCT05460273 - A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

November 7, 2023

Study Completion Date

December 31, 2025

Conditions

Carcinoma, Non-Small-Cell LungTriple Negative Breast Cancer

Interventions

DRUG

Datopotamab Deruxtecan (Dato-DXd)

Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.

Trial Locations (21)

100039

Research Site, Beijing

100044

Research Site, Beijing

100142

Research Site, Beijing

110042

Research Site, Shenyang

116023

Research Site, Dalian

130012

Research Site, Changchun

130021

Research Site, Changchun

150081

Research Site, Harbin

233004

Research Site, Bengbu

250030

Research Site, Jinan

250117

Research Site, Jinan

310022

Research Site, Hangzhou

330006

Research Site, Nanchang

330009

Research Site, Nanchang

350001

Research Site, Fuzhou

400030

Research Site, Chongqing

430022

Research Site, Wuhan

430030

Research Site, Wuhan

510060

Research Site, Guangzhou

510100

Research Site, Guangzhou

610000

Research Site, Chengdu